Shumei Kato, MD

University of California San Diego

Poster(s):

• (P 179) NEOADJUVANT AVAPRITINIB IN PDGFRA-MUTANT GIST: NEAR COMPLETE PATHOLOGICAL RESPONSES AT THE COST OF HIGH ADVERSE EVENT RATES

• (P 180) COMPARATIVE EFFICACY OF GENERIC AND BRAND-NAME IMATINIB IN NEOADJUVANT TREATMENT OF KIT EXON 11 MUTANT GIST